Reaching hypertriglyceridemia goals

References

• Pintó X, Valdivielso P, Perez de Juan JM, et al. on behalf of the Spanish Registry of Hypertriglyceridemia (Spanish Society of Arteriosclerosis, SAS). Curr Med Res Opin 2014;30:19-26
   Google Scholar
• Di Daniele N, Petramala L, Di Renzo L, et al. Body composition changes and cardiometabolic benefits of a balanced Italian Mediterranean Diet in obese patients with metabolic syndrome. Acta Diabetol 2013;50:409–16
   PubMed Web of Science ®Google Scholar
• Kesse-Guyot E, Ahluwalia N, Lassale C, et al. Adherence to Mediterranean diet reduces the risk of metabolic syndrome: a 6-year prospective study. Nutr Metab Cardiovasc Dis 2013;23:677–83
   PubMed Web of Science ®Google Scholar
• Defoort C, Vincent-Baudry S, Lairon D. Effects of 3-month Mediterranean-type diet on postprandial TAG and apolipoprotein B48 in the Medi-RIVAGE cohort. Public Health Nutr 2011;14:2302–8
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011;9:258–70
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Mikhailidis DP, Nordestgaard BG, et al. Definition of postprandial lipaemia. Curr Vasc Pharmacol 2011;9:292–301
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011;9:533–71
   PubMed Web of Science ®Google Scholar
• Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314–24
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916–22
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873–83
   PubMed Web of Science ®Google Scholar
• Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011;7:796–805
   PubMed Web of Science ®Google Scholar
• Migdalis I, Efthimiadis A, Pappas S, et al. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin 2009;25:2571–6
   PubMed Web of Science ®Google Scholar
• Fras Z, Mikhailidis DP. Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Curr Med Res Opin 2008;24:2467–76
   PubMed Web of Science ®Google Scholar
• Shigematsu E, Yamakawa T, Taguri M, et al. Efficacy of Ezetimibe is associated with gender and baseline lipid levels in patients with Type 2 Diabetes. J Atheroscler Thromb. 2012;19:846-53
   Google Scholar
• Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66B–9B
   PubMed Web of Science ®Google Scholar
• Hiramitsu S, Miyagishima K, Ishii J, et al. Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardiol 2012;60:395–400
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Nezu U, Inazumi K, et al. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb 2012;19:1093–101
   PubMed Web of Science ®Google Scholar
• Yunoki K, Nakamura K, Miyoshi T, et al. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 2011;217:486–91
   PubMed Web of Science ®Google Scholar
• Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009;39:689–98
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5
   PubMed Web of Science ®Google Scholar
• Lioudaki E, Vrentzos GE, Mavrogeni H, et al. Prevalence of metabolic syndrome according to different definitions in a hypertensive population. Angiology 2012;63:39–47
   PubMed Web of Science ®Google Scholar
• Athyros VG, Ganotakis ES, Tziomalos K, et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin 2010;26:713–9
   PubMed Web of Science ®Google Scholar
• , European Association for Cardiovascular Prevention & RehabilitationReiner Z, Catapano AL, De Backer G, et al.; ESC Committee for Practice Guidelines (CPG) 2008–2010, 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769–818
   Google Scholar
• Wierzbicki AS, Clarke RE, Viljoen A, et al. Triglycerides: a case for treatment? Curr Opin Cardiol 2012;27:398–404
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Papageorgiou AA, et al.; GREACE Study Collaborative Group. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids 2007;42:999–1009
   PubMed Web of Science ®Google Scholar